Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Earnings Results, Beats Expectations By $0.15 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced its earnings results on Tuesday. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating analysts’ consensus estimates of $6.49 by $0.15, FiscalAI reports. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 7.03%. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the business earned $6.51 EPS. The company’s quarterly revenue was up 8.1% compared to the same quarter last year.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Zanidatamab (Ziihera) delivered practice‑changing Phase III data in first‑line HER2‑positive metastatic GEA, received FDA Breakthrough Designation, and Jazz plans an sBLA with a potential launch in the second half of 2026, creating a multi‑tumor commercial opportunity.
• Jazz reported record 2025 revenue of $4.3 billion and Q4 revenue of $1.2 billion, but 2026 guidance of $4.25–$4.50 billion implies slower growth as the company increases R&D investment while managing sleep market headwinds.
• XYWAV remains the leading low‑sodium oxybate with strong patient adds, but the entry of multiple generic high‑sodium oxybate products and potential payer actions could meaningfully pressure the sleep franchise in the back half of 2026.
• Modeyso (from the Chimerix acquisition) launched in August and generated $48 million in 2025, with Jazz estimating a U.S. peak sales opportunity of >$500 million if adoption expands beyond academic centers.
• Epidiolex reached blockbuster sales of $1.1 billion in 2025 with continued volume growth, and settlement of ANDA litigation extended its commercial runway into the very late 2030s, supporting long‑term revenue stability.

Jazz Pharmaceuticals Trading Up 13.2%

JAZZ opened at $196.83 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. The stock’s 50 day moving average price is $168.72 and its 200-day moving average price is $150.60. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $197.47. The stock has a market cap of $11.96 billion, a price-to-earnings ratio of -32.97, a P/E/G ratio of 0.93 and a beta of 0.26.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 2,238 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the sale, the senior vice president directly owned 19,508 shares in the company, valued at $3,306,801.08. This represents a 10.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $171.20, for a total transaction of $797,792.00. Following the completion of the sale, the chief accounting officer owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Strategic Investment Advisors MI acquired a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $233,000. Quantessence Capital LLC acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $212,000. Graham Capital Management L.P. purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $206,000. UMB Bank n.a. lifted its position in shares of Jazz Pharmaceuticals by 12.6% during the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 81 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Jazz Pharmaceuticals by 53.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 902 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 313 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q4 beat — Jazz reported EPS of $6.64 vs. street ~ $6.49 and revenue of $1.20B vs. ~$1.17B, with revenue up ~8% YoY; investors are cheering the underlying sales strength. Article Title
• Positive Sentiment: 2026 guidance & portfolio momentum — Management guided 2026 revenue to $4.25B–$4.50B, highlighted an sBLA submission under RTOR for zanidatamab and continued strong launches (Modeyso initial traction), supporting forward growth expectations. Article Title
• Positive Sentiment: Key product drivers — Xywav posted strong growth (reported ~$1.7B in 2025) and Epidiolex also grew ~9% YoY; these franchises are supporting recurring revenue growth. Article Title
• Positive Sentiment: Analyst optimism — Multiple firms raised price targets (Bank of America to $275, Wells Fargo to $250, Morgan Stanley to $226, others), increasing buy/overweight sentiment and providing additional buy-side support. Article Title
• Neutral Sentiment: Investor materials & transcript available — The earnings presentation and full call transcript are published (useful for modeling and tracking management commentary on launches and zanidatamab timing). Article Title
• Negative Sentiment: Profitability nuance — Despite beat, the company still showed a negative net margin in the quarter (driven by charges/expenses), a reminder to watch margin recovery and one-time items. Article Title

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of analyst reports. Royal Bank Of Canada lifted their target price on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Piper Sandler restated an “overweight” rating and issued a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Robert W. Baird increased their price target on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Finally, Bank of America lifted their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $212.86.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.